Dabigatran Etexilate, 75 mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-474-60
Published December 18, 2024 · Recall initiated: December 12, 2024
Summary
FDA records drug Class II recall D-0129-2025, published December 18, 2024 and initiated December 12, 2024. Recalling firm: Ascend Laboratories, LLC; Status: Ongoing; Reported quantity: 1971 bottles; Lot: Lot #: 24142328, 24142329, 24142330, Exp. Date May 31, 2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
What to do
Voluntary: Firm initiated · Letter
Get an email if DABIGATRAN ETEXILATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- DABIGATRAN ETEXILATE
- Manufacturer
- Ascend Laboratories, LLC
- Distributor
- Nationwide within the United States
- UPC
- 0367877624600
- Lot
- Lot #: 24142328, 24142329, 24142330, Exp. Date May 31, 2026.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDADabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only,August 5, 2026
- FDADabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only,August 5, 2026
- FDADabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only,August 5, 2026
- FDADabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories,July 29, 2026
- FDALevothyroxine Sodium Tablets USP, 112 mcg, packaged in a) 90-count bottles (NDC 0378-1811-77) and b)December 18, 2024
- FDADabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd.,December 18, 2024
Questions about this recall
Was Dabigatran Etexilate, 75 mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-474-60 recalled?
Yes. FDA published recall D-0129-2025 on December 18, 2024. Reported hazard: CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: DABIGATRAN ETEXILATE. UPC: 0367877624600.